Ozomet-G2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination of these two agents offers complementary mechanisms of action, providing effective glycemic control in patients inadequately managed by diet and exercise alone. Ozomet-G2 Tablet PR is formulated for prolonged release, allowing for sustained therapeutic plasma concentrations, improved patient compliance, and reduced dosing frequency. It is recommended to be used alongside lifestyle modifications including diet and physical activity. Dosage should be individualized based on patient response and tolerability, with regular monitoring of blood glucose and renal function. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare lactic acidosis. Ozomet-G2 Tablet PR should be prescribed under medical supervision with appropriate patient education to optimize therapeutic outcomes and minimize risks.